<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2017.63015</article-id><article-id pub-id-type="publisher-id">HJO-22146</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20170300000_90526444.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  白内障合并糖尿病非增殖性视网膜病变患者术前局部使用双氯芬酸钠降低眼内IL-12浓度
  Cataract Combined with Diabetic Non-Proliferative Retinopathy Reduced the Concentration of IL-12 in the Eye with Diclofenac
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>素芳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>磊峰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>晓娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>董</surname><given-names>秋燕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>殊琪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>武警北京总队第二医院，北京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>08</month><year>2017</year></pub-date><volume>06</volume><issue>03</issue><fpage>88</fpage><lpage>93</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨白内障合并糖尿病非增殖性视网膜病变患者行白内障摘除手术前，局部使用双氯芬酸钠是否降低房水中IL-12浓度。方法：选取在我院拟接受手术治疗的38例白内障合并糖尿病非增殖性视网膜病变患者，随机分配为双氯芬酸钠观察组组和安慰剂对照组，对比分析两组研究对象房水中IL-12水平。其中双氯芬酸钠组17名，安慰剂组21名。双氯芬酸钠组患者在行白内障手术前10天，局部使用0.1%双氯芬酸钠4/日，术后继续用药30天。安慰剂组患者术前局部使用安慰剂10天，4/日，术后规范使用白内障术后用药共30天。所有患者术后均使用抗生素预防感染(妥布霉素滴眼液4/日)，术后用药时间为30天。白内障手术术前收集房水样本用以测量IL-12浓度。结果：双氯芬酸钠组患者房水中IL-12浓度明显低于安慰剂组。结论：IL-12在发生黄斑水肿的糖尿病性白内障患者房水中明显升高。此类患者行超声乳化吸除术后联合植入人工晶体治疗时，于术前应用双氯芬酸钠，术后联合抗生素类药物治疗，可有效减少黄斑水肿的发生，提高术后视力。
    Objective: To investigate whether the partial use of diclofenac sodium in the treatment of cataract combined with diabetic non-proliferative retinopathy can reduce IL-12 concentration in the aqueous water. Methods: 38 cases of cataract patients with diabetes mellitus not hyperplastic ret-inopathy to accept the surgical treatment in our hospital, are randomly assigned for diclofenac so-dium observation way and the placebo group, aqueous humor IL-12 levels are compared in re-search object of the two groups. There were 17 in diclofenac sodium and 21 in the placebo group. The patients of diclofenac sodium group were treated with 0.1% diclofenac 4/d and 30 days after surgery for 10 days before cataract surgery. In the placebo group, patients were given a placebo 10 days, 4/d, and postoperative standardized use of cataract surgery for 30 days. All patients were treated with antibiotic prophylaxis (tobramycin eye drops 4/d) after surgery and 30 days after surgery. Water samples collected before the operation of cataract was used to measure IL-12 con-centration. Result: The concentration of IL-12 in the patients with diclofenac sodium was signifi-cantly lower than that in the placebo group. Conclusion: IL-12 was significantly elevated in diabetic patients with diabetic cataract. Such patients when get ultrasonic emulsification therapy gettering postoperative combined implantation of artificial crystal, should apply the preoperative diclofenac sodium, combine postoperative antibiotic drug therapy, which can effectively reduce the occurrence of macular edema, improve visual acuity. 
  
 
</p></abstract><kwd-group><kwd>白内障，糖尿病，双氯芬酸钠，白介素-12, Cataract</kwd><kwd> Diabetes</kwd><kwd> Sodium Diclofenac</kwd><kwd> Interleukin 12</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>白内障合并糖尿病非增殖性视网膜病变患者术前局部使用双氯芬酸钠降低眼内IL-12浓度<sup> </sup></title><p>朱素芳，王磊峰，李晓娟，董秋燕，宋殊琪</p><p>武警北京总队第二医院，北京</p><p>收稿日期：2017年8月22日；录用日期：2017年9月16日；发布日期：2017年9月25日</p><disp-formula id="hanspub.22146-formula8"><graphic xlink:href="//html.hanspub.org/file/3-2230158x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨白内障合并糖尿病非增殖性视网膜病变患者行白内障摘除手术前，局部使用双氯芬酸钠是否降低房水中IL-12浓度。方法：选取在我院拟接受手术治疗的38例白内障合并糖尿病非增殖性视网膜病变患者，随机分配为双氯芬酸钠观察组组和安慰剂对照组，对比分析两组研究对象房水中IL-12水平。其中双氯芬酸钠组17名，安慰剂组21名。双氯芬酸钠组患者在行白内障手术前10天，局部使用0.1%双氯芬酸钠4/日，术后继续用药30天。安慰剂组患者术前局部使用安慰剂10天，4/日，术后规范使用白内障术后用药共30天。所有患者术后均使用抗生素预防感染(妥布霉素滴眼液4/日)，术后用药时间为30天。白内障手术术前收集房水样本用以测量IL-12浓度。结果：双氯芬酸钠组患者房水中IL-12浓度明显低于安慰剂组。结论：IL-12在发生黄斑水肿的糖尿病性白内障患者房水中明显升高。此类患者行超声乳化吸除术后联合植入人工晶体治疗时，于术前应用双氯芬酸钠，术后联合抗生素类药物治疗，可有效减少黄斑水肿的发生，提高术后视力。</p><p>关键词 :白内障，糖尿病，双氯芬酸钠，白介素-12</p><disp-formula id="hanspub.22146-formula9"><graphic xlink:href="//html.hanspub.org/file/3-2230158x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>我国有将近1.14亿糖尿病患者 [<xref ref-type="bibr" rid="hanspub.22146-ref1">1</xref>] ，其中糖尿病视网膜病变是其主要的并发症之一，同时糖尿病也可加速白内障的进展 [<xref ref-type="bibr" rid="hanspub.22146-ref2">2</xref>] 。白内障合并糖尿病非增殖性视网膜病变患者临床上以手术治疗为主，但术后患者多并发黄斑水肿的发病率在0.10%~2.30% [<xref ref-type="bibr" rid="hanspub.22146-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.22146-ref4">4</xref>] ，严重时可影响患者术后视力，甚至有致盲的可能性 [<xref ref-type="bibr" rid="hanspub.22146-ref5">5</xref>] 。</p><p>黄斑水肿初期视网膜黄斑区中心凹周围扩张的毛细血管内渗出血液成分而导致的黄斑增厚，之后逐渐在外丛状层和内丛状层积聚，形成黄斑囊样水肿 [<xref ref-type="bibr" rid="hanspub.22146-ref6">6</xref>] 。目前认为，黄斑囊样水肿多与手术本身引起的血-房水屏障破坏释放以前列腺素为主的炎症介质有关 [<xref ref-type="bibr" rid="hanspub.22146-ref7">7</xref>] 。</p><p>双氯芬酸钠可抑制眼内环氧化酶活性，而环氧化酶是前列腺素生物合成重要的酶 [<xref ref-type="bibr" rid="hanspub.22146-ref8">8</xref>] 。双氯芬酸钠临床多用于控制白内障摘除术后炎症反应，缓解疼痛，还能减轻角膜切口引起的畏光反应 [<xref ref-type="bibr" rid="hanspub.22146-ref9">9</xref>] 。</p></sec><sec id="s4"><title>2. 对象与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>选取2013年1月至2014年12月期间在我院眼科收治的38例白内障患者，合并非增殖性糖尿病视网膜病变，接受白内障摘除手术。患者接受口头及书面告知，对照组患者签知情同意书。</p><p>入组标准：年龄 &gt; 60岁；依据ETDRS分级，糖尿病视网膜病变为轻中级；依据LOCS分级，LOCS III为2~3级。</p><p>排除标准：同时患有急性或慢性眼病的(葡萄膜炎、视网膜中央静脉阻塞、视网膜分支静脉阻塞、视网膜前膜)；曾行视网膜激光光凝术；对双氯芬酸钠过敏的；口服抗凝药物的。</p><p>入组患者随机分为双氯芬酸钠观察组17人和安慰剂对照组21人，局部点眼药瓶无标签，以便保证患者与检查者对于治疗方案是双盲的。</p></sec><sec id="s4_2"><title>2.2. 方法</title><p>入组患者施行统一的检查标准。首次接诊时签患者知情同意书，由同一名医师进行全面的眼科检查，包括最佳矫正视力、Goldmann压平眼压计测眼压、裂隙灯显微镜检查眼部前节、双目间接检眼镜查眼底、眼底照相、OCT测量黄斑厚度。之后在白内障手术前10天、手术当天以及术后1、7、30、90天均行眼科检查。</p><p>实验组患者术前10天开始局部点0.1%双氯芬酸钠，4/日，术后30天停药。对照组患者术前10天局部点安慰剂，术后按标准化治疗用药，即局部点0.1%氟美松4/日，妥布霉素滴眼液预防感染4/日，术后30天停药。</p><p>实验组和对照组患者均在白内障手术开始时，由术者进行前房穿刺，收集0.2 ml房水置于标本管冷藏待测。采用酶联免疫吸附法检测房水中IL-12水平含量。所有操作均按照试剂盒说明书进行。术后1 d、7 d、30 d，两组患者局部点复方托吡卡胺滴眼液散大瞳孔后，取坐位，由同一名医师行双目间接检眼镜检查眼底。然后利用光学相干断层扫描仪对患者进行黄斑检查，记录是否有水肿。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>1) 本研究入组患者38名(23男、15女)，平均年龄66.5 &#177; 8.4岁，平均病程15 (8~32)年。观察组和对照组在年龄、性别和糖尿病病程方面无明显差异(见表1)。术后1 d、7 d、30 d患者最佳矫正视力情况明显改善。</p><p>2) 作为反映炎症的指标，观察组和对照组房水中IL-12浓度。在观察组(27.4 &#177; 14.8 ug/ml)明显低于对照组(43.7 &#177; 19.6 ug/ml)。</p><p>3) 术后发生黄斑水肿情况：术后通过散瞳处理后在双目间接检眼镜下检查患者眼底，观察组发现2只患眼并发黄斑水肿，占11.8%，对照组为6只，占28.6%，差异有统计学意义(P &lt; 0.05)。采用OCT检查发现，观察组发现3只患眼并发黄斑水肿，占17.6%，对照组为7只，占33.3%，差异有统计学意义(P &lt; 0.05)。见表2。</p></sec><sec id="s6"><title>4. 讨论</title><p>白内障是糖尿病常见的并发症之一，其中以老年人居多，严重影响患者生活质量 [<xref ref-type="bibr" rid="hanspub.22146-ref10">10</xref>] 。超声乳化吸除白内障并植入人工晶体是临床治疗白内障的主要方式 [<xref ref-type="bibr" rid="hanspub.22146-ref11">11</xref>] 。Kim、Litvin [<xref ref-type="bibr" rid="hanspub.22146-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.22146-ref13">13</xref>] 等针对糖尿病性白内障患者行超声乳化联合人工晶体植入治疗，术后患者并发黄斑水肿的概率为10%~15%。因此，如何防止术后并发黄斑囊样水肿是目前眼科亟待解决的重要问题。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of two groups in genera</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >分组</th><th align="center" valign="middle"  rowspan="2"  >眼数</th><th align="center" valign="middle"  rowspan="2"  >性别(男/女)</th><th align="center" valign="middle"  rowspan="2"  >年龄</th><th align="center" valign="middle"  colspan="2"  >高血压病史</th><th align="center" valign="middle"  rowspan="2"  >糖尿病病程</th></tr></thead><tr><td align="center" valign="middle" >有</td><td align="center" valign="middle" >无</td></tr><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >10 (58.8%)/7 (41.2%)</td><td align="center" valign="middle" >67.23 &#177; 9.37</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >17.6 (5~35)</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >13 (61.9%)/8 (38.1%)</td><td align="center" valign="middle" >66.85 &#177; 7.51</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >16.9 (10~28)</td></tr></tbody></table></table-wrap><p>表1. 两组研究对象一般情况比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Postoperative macular edema (eyes, (%)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >眼数</th><th align="center" valign="middle" >间接检眼镜检查</th><th align="center" valign="middle" >OCT</th></tr></thead><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >2 (11.8)</td><td align="center" valign="middle" >3 (17.6)</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >6 (28.6)</td><td align="center" valign="middle" >7 (33.3)</td></tr><tr><td align="center" valign="middle" >X2值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >3.764</td><td align="center" valign="middle" >3.851</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.045</td><td align="center" valign="middle" >0.043</td></tr></tbody></table></table-wrap><p>表2. 两组研究对象术后发生黄斑水肿(眼，(%))</p><p>近年来，文献报道关于房水中细胞因子的研究越来越多，很多作者都在研究糖尿病患者房水中多种细胞因子，包括IL-6、IL-8 [<xref ref-type="bibr" rid="hanspub.22146-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.22146-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.22146-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.22146-ref15">15</xref>] 、TGF-β2、FGF、MCP-4 [<xref ref-type="bibr" rid="hanspub.22146-ref16">16</xref>] ，发现较非糖尿病患者明显升高。其中，IL-12由人类树突状细胞和巨噬细胞分泌，在损伤和伤口愈合时分泌增加 [<xref ref-type="bibr" rid="hanspub.22146-ref15">15</xref>] 。其生物活性为增加NK细胞的杀伤力，增加CD8+T淋巴细胞特异性细胞毒活性 [<xref ref-type="bibr" rid="hanspub.22146-ref15">15</xref>] 。在糖尿病患者房水中促炎症因子浓度增加提示患者有亚临床眼内炎症 [<xref ref-type="bibr" rid="hanspub.22146-ref6">6</xref>] 。同样，我们发现房水中IL-12与白内障术后黄斑水肿的发生亦有关。术前局部应用双氯芬酸钠可明显降低房水中IL-12浓度，降低术前糖尿病视网膜病变引发的眼内炎症，也降低超乳术后黄斑水肿的发生。</p><p>黄斑囊样水肿的发病机制不明，可能因外科手术创伤使患者前列腺素类炎性物质增多 [<xref ref-type="bibr" rid="hanspub.22146-ref17">17</xref>] ；也可能与术中眼压波动，晶体后囊破裂，玻璃体脱出牵拉黄斑区 [<xref ref-type="bibr" rid="hanspub.22146-ref18">18</xref>] ；显微镜的光毒性 [<xref ref-type="bibr" rid="hanspub.22146-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.22146-ref20">20</xref>] 等。临床针对白内障术后并发黄斑水肿患者常采用药物治疗、激光治疗以及外科手术治疗等。其中，林为华等 [<xref ref-type="bibr" rid="hanspub.22146-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.22146-ref22">22</xref>] 学者报道，雷珠单抗作为高效血管内皮生长因子抑制剂，用于白内障术后降低黄斑水肿发生的概率为13.0%，显著低于常规治疗。</p><p>此外，临床较多学者研究报道非甾体类消炎镇痛药(NSAIDs)，如双氯芬酸钠 [<xref ref-type="bibr" rid="hanspub.22146-ref6">6</xref>] 、0.45%酮铬酸 [<xref ref-type="bibr" rid="hanspub.22146-ref23">23</xref>] 、0.1%溴芬酸钠 [<xref ref-type="bibr" rid="hanspub.22146-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.22146-ref24">24</xref>] 、0.3%奈帕芬胺 [<xref ref-type="bibr" rid="hanspub.22146-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.22146-ref26">26</xref>] ，均有报道可用于预防简单白内障术后并发黄斑水肿。本文研究双氯芬酸钠通过抑制眼内环氧化酶活性，达到减少合成白三烯，预防术后黄斑水肿。0.1%溴芬酸钠、0.3%奈帕芬胺等作为新型NSAID制剂，具有渗透力更强、起效快的特点，其中0.3%奈帕芬胺对前列腺素有独特的靶向抑制作用 [<xref ref-type="bibr" rid="hanspub.22146-ref27">27</xref>] ，Kern [<xref ref-type="bibr" rid="hanspub.22146-ref28">28</xref>] Heier [<xref ref-type="bibr" rid="hanspub.22146-ref29">29</xref>] 等都发现奈帕芬胺可有效治疗黄斑水肿。</p><p>综上所述，IL-12在发生黄斑水肿的糖尿病性白内障患者房水中明显升高。此类患者行超声乳化吸除术后联合植入人工晶体治疗时，于术前应用双氯芬酸钠，术后联合抗生素类药物治疗，可有效减少黄斑水肿的发生，提高术后视力。</p></sec><sec id="s7"><title>文章引用</title><p>朱素芳,王磊峰,李晓娟,董秋燕,宋殊琪. 白内障合并糖尿病非增殖性视网膜病变患者术前局部使用双氯芬酸钠降低眼内IL-12浓度Cataract Combined with Diabetic Non-Proliferative Retinopathy Reduced the Concentration of IL-12 in the Eye with Diclofenac[J]. 眼科学, 2017, 06(03): 88-93. http://dx.doi.org/10.12677/HJO.2017.63015</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.22146-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Xu, Y., Wang, L., He, J., et al. (2013) Prevalence and Control of Diabetes in Chinese Adults. JAMA, 310, 948-959.  
&lt;br&gt;https://doi.org/10.1001/jama.2013.168118</mixed-citation></ref><ref id="hanspub.22146-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Czik, T., Sobota, I., Slugan, I., Jambrek, B., Pavicic-Astalos, J. (2006) Causes of Blindness in 25% of the Blind Population in Croatia and the Possibilities of Prevention. Acta medica Croatica, 60, 159-161.</mixed-citation></ref><ref id="hanspub.22146-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">董宁, 汤欣, 肖林, 等. 房水中多种细胞因子与2型糖尿病患者白内障术后黄斑水肿的关系[J]. 中华实验眼科杂志, 2015, 33(4): 356-361.</mixed-citation></ref><ref id="hanspub.22146-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">李红伟, 王晋峰, 王春芳. 非甾体类消炎药预防糖尿病患者白内障术后黄斑水肿的临床观察[J]. 中华临床医师杂志(电子版), 2016, 10(9): 1345-1348.</mixed-citation></ref><ref id="hanspub.22146-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">郭媛, 张杰, 张春刚. 2型糖尿病患者行白内障手术后黄斑水肿状况研究[J]. 中华临床医师杂志(电子版), 2015, 9(14): 2662-2664.</mixed-citation></ref><ref id="hanspub.22146-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Medić, A., Jukić, T., Matas, A., Vukojević, K., Sapunar, A. and Znaor, L. (2017) Effect of Preopera-tive Topical Diclofenac on Intraocular Interleukin-12 Concentration and Macular Edema after Cataract Surgery in Patients with Diabetic Retinopathy: A Randomized Controlled Trial. Croatian Medical Journal, 58, 49-55.  
&lt;br&gt;https://doi.org/10.3325/cmj.2017.58.49</mixed-citation></ref><ref id="hanspub.22146-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">王丹丹, 冯一帆, 廉恒丽, 等. 非甾体类抗炎药不同给药方式对微切口白内障术后黄斑厚度的影响[J]. 中华眼视光学与视觉科学杂志, 2015, 17(8): 488-492.</mixed-citation></ref><ref id="hanspub.22146-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">李超, 李斌, 郑波涛, 等. 糖尿病黄斑水肿患者白内障术中玻璃体腔注射曲安奈德的临床观察[J]. 中国眼耳鼻喉科杂志, 2015, 15(1): 32-35.</mixed-citation></ref><ref id="hanspub.22146-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">张红言, 朱思泉. 普拉洛芬滴眼液预防白内障术后黄斑囊样水肿的临床研究[J]. 国际眼科杂志, 2008, 8(7): 1370-1372.</mixed-citation></ref><ref id="hanspub.22146-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Tsaousis, K.T., Panagiotou, D.Z., Kostopoulou, E., Vlatsios, V., Stam-pouli, D. (2016) Corneal Oedema after Phacoemulsification in the Early Postoperative Period: A Qualitative Comparative Case-Control Study between Diabetics and Non Diabetics. Annals of Medicine Surgery, 5, 67-71. &lt;br&gt;https://doi.org/10.1016/j.amsu.2015.12.047</mixed-citation></ref><ref id="hanspub.22146-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">丁国龙, 谢安明, 雷剑琴, 丁国鹏, 胡亚光. 增生型糖尿病视网膜病变患者玻璃体内注射贝伐单抗后房水中细胞因子的变化及其相关性分析[J]. 眼科新进展, 2017, 37(4): 358-361.</mixed-citation></ref><ref id="hanspub.22146-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kim, S.J., Flach, A.J., Jampol, L.M., et al. (2010) Nonsteroidal Anti-Inflammatory Drugs in Ophthal-mology. Survey of Ophthalmology, 55, 108-133.</mixed-citation></ref><ref id="hanspub.22146-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Litvin, T.V., Ozawa, G.Y., Bresnick, G.H., et al. (2014) Utility of Hard Exudates for the Screening of Macular Edema. Optometry and Vision Science, 91, 370-375. &lt;br&gt;https://doi.org/10.1097/OPX.0000000000000205</mixed-citation></ref><ref id="hanspub.22146-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">褚俏梅, 李方都, 张树芬, 唐琴, 陆艳. 糖尿病性白内障房水中细胞因子IGF-1、bFGF和IL-6的含量测定[J]. 眼科新进展, 2010, 30(6): 531-533.</mixed-citation></ref><ref id="hanspub.22146-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Gverović Antunica, A., Karaman, K., Znaor, L., Sapunar, A., Busko, V. and Puzovic, V. (2012) IL-12 Concentrations in the Aqueous Humor and Serum of Diabetic Retinopathy Patients. Graefe’s Archive for Clinical and Experimental Ophthalmology, 250, 815-821. &lt;br&gt;https://doi.org/10.1007/s00417-011-1905-4</mixed-citation></ref><ref id="hanspub.22146-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">宋蔚, 赵帅, 任百超, 郅瑛. 2型糖尿病患者白内障术后黄斑水肿与房水中TGF-β2、FGF及MCP-1的研究[J]. 临床眼科杂志, 2016, 24(5): 385-387.</mixed-citation></ref><ref id="hanspub.22146-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Deepak, K.S. and Sivaswamy, J. (2012) Automatic Assessment of Macular Edema From Color Retinal Images. IEEE Trans Med Imaging, 31, 766-776. &lt;br&gt;https://doi.org/10.1109/TMI.2011.2178856</mixed-citation></ref><ref id="hanspub.22146-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">李佳佳, 陈彬川, 帖红艳, 等. 白内障超声乳化吸出联合人工晶状体植入术高危因素临床分析[J]. 眼科新进展, 2014, 34(5): 448-450.</mixed-citation></ref><ref id="hanspub.22146-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ghosh, S., Roy, I., Biswas, P.N., et al. (2010) Prospective Randomized Comparative Study of Macular Thickness Following Phacoemulsification and Manual Small Incision Cataract Surgery. Acta Ophthalmologica, 88, 102-106.  
&lt;br&gt;https://doi.org/10.1111/j.1755-3768.2010.01896.x</mixed-citation></ref><ref id="hanspub.22146-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Lobo, C. (2012) Pseudophakic Cystoid Macular Edema. Ophthalmologica, 227, 61-67.  
&lt;br&gt;https://doi.org/10.1159/000331277</mixed-citation></ref><ref id="hanspub.22146-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">林为华, 卢敏, 唐浩英, 曾昭荣. 雷珠单抗在糖尿病性白内障治疗中的临床应用[J]. 国际眼科杂志, 2015, 5(15): 880-882.</mixed-citation></ref><ref id="hanspub.22146-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Fong, A.H. and Lai, T.Y. (2013) Long-Term Effectiveness of Ranibizumab for Agerelated Macular Degeneration and Diabetic Macular Edema. Clinical Interventions in Aging, 8, 467-483.</mixed-citation></ref><ref id="hanspub.22146-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Donnenfeld, E.D., Nichamin, L.D., Hardten, D.R., Raizman, M.B., Trattler, W., Rajpal, R.K., et al. (2011) Twice-Daily, Preservative-Free Ketorolac 0.45% for Treatment of Inflammation and Pain after Cataract Surgery. American Journal of Ophthalmology, 151, 420-426.</mixed-citation></ref><ref id="hanspub.22146-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Greenberg, P.B., Tseng, V.L., Wu, W.C., et al. (2011) Prevalence and Predictors of Ocular Complications Associated with Cataract Surgery in United States Veterans. Ophthalmology, 118, 507-514.</mixed-citation></ref><ref id="hanspub.22146-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">McCafferty, S., Harris, A., Kew, C., Kassm, T., Lane, L., Levine, J. and Raven, M. (2017) Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Study with Adjunctive Once Daily Topical Nepafenac 0.3% versus Placebo. BMC Ophthalmology, 17, 16. &lt;br&gt;https://doi.org/10.1186/s12886-017-0405-7</mixed-citation></ref><ref id="hanspub.22146-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Almeida, D., Khan, Z., Xing, L., Bakar, S., Rahim, K., Urton, T. and El-Defrawy, S. (2012) Prophylacticnepafenac and Ketorolac versus Placebo in Preventing Postoperative Macula-redema after Uneventful Phacoemulsification. Journal of Cataract &amp; Refractive Surgery, 38, 1537-1543.</mixed-citation></ref><ref id="hanspub.22146-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Walters, T., Raizman, M., Ernest, P., Gayton, J. and Lehmann, R. (2007) In Vivo Pharmacokinetics and in Vitro Pharmacody-namics of Nepafenac, Amfenac, Ketorolac, and Bromfenac. Journal of Cataract &amp; Refractive Surgery, 33, 1539-1545.</mixed-citation></ref><ref id="hanspub.22146-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Kern, T.S., Miller, C.M., Du, Y., Zheng, L., Mohr, S., Ball, S.L., Kim, M., Jamison, J.A. and Binga-man, D.P. (2007) Topical Administration of Nepafenac Inhibits Diabetes-Induced Retinal Microvascular Disease and Underlying Abnormalities of Retinal Metabolism and Physiology. Diabetes, 56, 373-379. &lt;br&gt;https://doi.org/10.2337/db05-1621</mixed-citation></ref><ref id="hanspub.22146-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Heier, J.S., Awh, C.C., Busbee, B.G., Waterbury, L.D., Daniel, P., Stoller, G.L. and Cleary, T.S. (2009) Vitreous Nonsteroidal Antiinflammatory Drug Concentrations and Prostaglandin E2 Levels in Vitrectomy Patients Treated with Ketorolac 0.4%, Bromfenac 0.09%, and Nepafenac 0.1%. Retina, 29, 1310-1313.  
&lt;br&gt;https://doi.org/10.1097/IAE.0b013e3181b094e6</mixed-citation></ref></ref-list></back></article>